Search

everythinglearnresearchcommunity

for

Search:↓

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Tofacitinib helped a woman regrow hair with no major side effects.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Biological therapy boosts the immune system to effectively fight melanoma.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

The rash resolved after stopping ponatinib.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Gefitinib can cause hair loss without scarring.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.